The Latest Breaking News from NIH

A new report says a shortage of monkeys available for medical research undermines U.S. readiness to respond to public health emergencies

WASHINGTON — The broad outlines of an upcoming debate over a pandemic preparedness reauthorization bill are beginning to emerge as regulators, policymakers and industry groups take stock of lessons learned from COVID-19.

A reauthorization of the pandemic preparedness law will give Congress a chance to revisit its handling of COVID-19.

WASHINGTON — Lawmakers are more interested in biomedical research than ever, but with limited funds for nondefense spending, experts worry the National Institutes of Health could end up in competition with the new agency the Biden administration wants to build to confront the toughest problems.

White House has proposed relatively flat funding for NIH and is seeking $1 billion increase for NIH's newer, flashier cousin, ARPA-H.

A decade after a landmark report on Americans' shorter lives, the problem has only gotten worse. Unlike other wealthy nations, U.S. life expectancy has not bounced back from the pandemic.

You might get the impression from the Biden administration's insulin price cut and its initiative allowing Medicare to negotiate over other pharmaceuticals that the drug pricing issue is finally being taken seriously in Washington.

WASHINGTON — Moderna CEO Stéphane Bancel attempted on Wednesday to win over lawmakers irate about the company’s planned COVID-19 vaccine price increase, weathering a barrage of criticism from Democrats angry at the company’s profits from its groundbreaking mRNA vaccine.

In a Senate hearing, Moderna's CEO tried to soothe lawmakers angry about plans to increase the cost of COVID-19 vaccines.

The veterinary tranquilizer has been linked to a growing number of overdose deaths across the country, especially in the Northeast. It's often combined with fentanyl, but can't be treated with Narcan.

The National Institutes of Health have been without a permanent director since the end of 2021. But not for lack of trying: At least two good prospects “have walked away,” according to the Wall Street Journal — not only out of concern that the role has become more politically contentious…